1Hanna N,Shepherd FA,Fossella FV,et al.Randomized phaseⅢtrial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22(9):1589-1597.
2Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phaseⅢtrial. Lancet,2008,372(9652):1809-1818.
3Ciuleanu T,Brodowicz T,Zielinski C,et al.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer:a randomised,double-blind,phase 3 study.Lancet,2009, 374(9699):1432-1440.
4Di Maio M,Chiodini P,Georgoulias V,et al.Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as secondline treatment of advanced non-small-cell lung cancer.J Clin Oncol,2009, 27(11):1836-1843.
5SAAB S, KIM M, WRIGHT T L, et al. Successful orthotopic liver transplanation forl amivudine-associated YMDD mutant hepatitis B virus[J]. Gastroenterology, 2000,119(5):1382-1384.
6LIAW Y F, CHIEN R N, YEH C T, et al. Acute exacerbation and hepatits B virus clearance after emergence of YMDD motif mutantion lamivudine therapy[J]. Hepatology,1999,20(2):567-572.
7PASTINEN T,RAITIO M,LINDROOS K,et al.A system for specific, high-throughout genotyping by allele specific primer extension on microarray[J].Genome Res,2000,10(7):1031-1042.
8NAFA S,AHEMD S, TAVAN D, et al. Early detection of viral resistance by determination of hepatits B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B[J]. Hepatology,2000,32(5):1078-1088.
9AllEN M I,DESLAURIERS M, ANDREWS C W, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine[J].Hepatology,1998,27(6):1670-1677.
